#	Pagina
attuale pagina	/open-h2020/projects/219940/index.html

Opendata, web and dolomites

PillSense SIGNED

Accelerating market introduction of the first real-time diagnistic and monitoring device for upper gastrointestinal bleeding (UGIB)

Total Cost €

EC-Contrib. €

Partnership

Views

PillSense project word cloud

Explore the words cloud of the PillSense project. It provides you a very rough idea of what is the project "PillSense" about.

ingestible contains culminates approval stages data 29million receiver tract invasive tests bleeding 2433 regulatory suspicion approvals annually life conclusive detect post lab 24months commercial generate potentially upper ultimately million detection clinical 59million capsule united hospital profit core laboratory expensive shows led vivo optimise monitoring fti bleed proven revenues subsequent commercialisation optical threatening disruptive endoscopy gain gastrointestinal mean enterasense trials successful gross ugib disciplinary external approx time endoscopic admission patients consequent pillsense prolonged slow human team people diagnosis sensor 60 manufacturing risk

Project "PillSense" data sheet

The following table provides information about the project.

Coordinator	ENTERASENSE LIMITED Organization address address: PENN ENGINEERING MERVUE BUSINESS AND TECHNOLOGY PA city: GALWAY postcode: H91D3T0 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Ireland [IE]
Total cost	3˙551˙437 €
EC max contribution	2˙675˙756 € (75%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-EIC-FTI-2018-2020
Funding Scheme	IA
Starting year	2019
Duration (year-month-day)	from 2019-01-01 to 2020-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ENTERASENSE LIMITED ENTERASENSE LIMITED Organization address address: PENN ENGINEERING MERVUE BUSINESS AND TECHNOLOGY PA city: GALWAY postcode: H91D3T0 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (GALWAY)	coordinator	1˙029˙831.00
2	FAKULTNI NEMOCNICE OSTRAVA FAKULTNI NEMOCNICE OSTRAVA Organization address address: 17 LISTOPADU 1790 city: OSTRAVA PORUBA postcode: 708 52 website: www.fno.cz contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CZ (OSTRAVA PORUBA)	participant	632˙500.00
3	STERIPACK MEDICAL POLAND SP ZOO STERIPACK MEDICAL POLAND SP ZOO Organization address address: UL. JAPONSKA 1 LEG city: JELCZ LASKOWICE postcode: 55 220 website: www.valcon.pl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PL (JELCZ LASKOWICE)	participant	554˙400.00
4	ANECTO LIMITED ANECTO LIMITED Organization address address: PENN ENGINEERING, MERVUE BUSINESS & TECHNOLOGY PAR city: GALWAY postcode: H91D3T0 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (GALWAY)	participant	459˙025.00

Map

Project objective

Upper gastrointestinal bleeding (UGIB) is a potentially life-threatening condition that affects approx. 2 million people annually in Europe and in the United States. Current UGIB diagnosis comprises a long and slow set of laboratory tests and culminates ultimately with an endoscopy which is the only conclusive mean for UGIB diagnosis. This results in an over usage of endoscopic resources every time there is a suspicion of a bleed. Clinical data shows that up to 60% of the time endoscopy and consequent hospital admission is not necessary. In addition, endoscopy is invasive, expensive (approx. €2433) and cannot deliver prolonged monitoring. Multi-disciplinary consortium led by EnteraSense are developing a disruptive technology ‘PillSense’ which enables real-time detection of UGIB and subsequent monitoring of high risk patients without the need of endoscopy. The product includes an ingestible capsule and an external receiver. The capsule contains an optical based sensor to detect bleeding in the upper gastrointestinal tract. EnteraSense development team has already proven the core technology through lab-testing and in-vivo clinical studies. Through this 24months FTI project, the consortium aims to optimise PillSense product design, gain regulatory approvals, develop a commercial scale manufacturing process and gain clinical approval through two stages in-human clinical trials. Successful development and commercialisation will enable consortium to generate revenues of €59million and a gross profit of €29million over five years- post commercialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PILLSENSE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PILLSENSE" are provided by the European Opendata Portal: CORDIS opendata.